Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20213958 | 0.85 | SSTR4 (0.41) | SSTR4CDK1KDM4EGLAAAK1 | |
| SCHEMBL2713610 | 0.84 | SSTR4 (0.49) | SSTR4KDM4EAAK1CYP11B1CYP11B2 | |
| SCHEMBL29749337 | 0.83 | SSTR4 (0.44) | SSTR4HPGDSMN1; SMN2KDM4EAAK1 | |
| SCHEMBL13281923 | 0.83 | SSTR4 (0.52) | SSTR4AAK1CYP11B1CYP11B2S1PR4 | |
| SCHEMBL22638138 | 0.83 | SSTR4 (0.44) | SSTR4HPGDSMN1; SMN2KDM4EAAK1 | |
| SCHEMBL322071 | 0.82 | SSTR4 (0.42) | SSTR4CFTRCYP11B1CYP11B2S1PR4 | |
| SCHEMBL30851311 | 0.82 | SSTR4 (0.42) | SSTR4CFTRCYP11B1CYP11B2S1PR4 | |
| SCHEMBL19155888 | 0.81 | SSTR4 (0.44) | SSTR4CDK1CFTRRETKDM4E | |
| SCHEMBL17594774 | 0.80 | SSTR4 (0.34) | SSTR4HPGDSMN1; SMN2AAK1GRM5 | |
| SCHEMBL28527258 | 0.79 | CDK1 (0.41) | CDK1CFTRSMN1; SMN2RETKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| EP-2790705-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | Novartis AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-20140249139-A1 | Quinazoline Derivatives | NOVARTIS AG (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249139-A1 | Quinazoline Derivatives | NOVARTIS AG (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249139-A1 | Quinazoline Derivatives | NOVARTIS AG (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013057711-A1 | QUINAZOLINE DERIVATIVES AS PI3K MODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057711-A1 | QUINAZOLINE DERIVATIVES AS PI3K MODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | SSTR4 1772/4885CDK1 1153/4885CFTR 812/4885 |
| US-20140249139-A1 | Quinazoline Derivatives | XDH, PIK3CA, PIK3R4 | SSTR4 4339/4885CDK1 93/4885CFTR 410/4885 |
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | SSTR4 1340/4885CDK1 1857/4885CFTR 455/4885 |
| US-20100056582-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | SSTR4 1340/4885CDK1 1857/4885CFTR 455/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | SSTR4 3607/4885CDK1 1093/4885CFTR 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.